BioSpace News Archive

Novartis is scaling back its pipeline to focus on higher-value assets with stronger commercial potential.

During its Q1 earnings call Tuesday, Biogen announced a handful of program pauses and cuts and touted the potential of anticipated approvals.

Orbital will use Series A funds to advance RNA-based vaccines, immunomodulators and protein replacement therapies.

The proposed drug pricing legislations follow the Inflation Reduction Act, passed in August 2022.

Avenge Bio, Inc. today announced the successful completion of the first dose cohort in a Phase 1/2 clinical trial of AVB-001 in patients with refractory ovarian cancer.

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced positive topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

TransCode Therapeutics, Inc. today announced a strategic expansion of its diverse product portfolio.

Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, in partnership with Smile Train, the world’s largest cleft-focused organization, and FDI, the global voice of the dental profession, are proud to announce a major milestone in the push to advance global cleft care.

Calico Life Sciences LLC today announced that the first participant has been dosed in a Phase 1b clinical trial, (study M23-523; NCT05757141), evaluating the investigational eIF2B activator ABBV-CLS-7262 as a potential treatment for Vanishing White Matter (VWM) disease.

RG6501 (OpRegen ® ) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration.